Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EDP-938 Dose 1 · 1 trial · 1 indication
Measured in nasal washes by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in participants inoculated with respiratory syncytial virus-A (RSV-A) Memphis 37b.
| Arm | Type | Description |
|---|---|---|
| EDP-938 Arm A | EXPERIMENTAL | Subjects will take EDP-938 Dose 1 oral suspension for 5 days |
| EDP-938 Arm B | EXPERIMENTAL | Subjects will take EDP-938 Dose 2 oral suspension for 5 days |
| Placebo Arm C | PLACEBO_COMPARATOR | Subjects will take matching placebo oral suspension for 5 days |
| EDP-938 Arm D | EXPERIMENTAL | Subjects will take EDP-938 Dose 3 oral suspension for 5 days |
| EDP-938 Arm E | EXPERIMENTAL | Subjects will take EDP-938 Dose 4 oral suspension for 5 days |
| Placebo Arm F | PLACEBO_COMPARATOR | Subjects will take matching placebo oral suspension for 5 days |
| Name | Type | Description |
|---|---|---|
| EDP-938 Dose 1 | DRUG | Oral suspension for 5 days |
| EDP-938 Dose 2 | DRUG | Oral suspension for 5 days |
| Placebo | DRUG | Oral suspension for 5 days |
| EDP-938 Dose 3 | DRUG | Oral suspension for 5 days |
| EDP-938 Dose 4 | DRUG | Oral suspension for 5 days |
Inclusion Criteria: * An informed consent document signed and dated by the subject * Age 18 to 55 years, inclusive * In good health with no history of major medical conditions * A total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m\^2 and ≤ 30kg/m\^2 Exclusion Criteria: * Pregnant or nu...
Top 20 of 28 competitors
EDP-305 Dose 1 is an investigational small molecule being studied for the treatment of Non-Alcoholic Steatohepatitis (NASH) and RSV Infection. It is being developed by Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
EDP-305 Dose 1 is a small molecule being developed for Non-Alcoholic Steatohepatitis and RSV Infection. The specific molecular target has not been disclosed in available information. The drug is currently in Phase 2 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and efficacy.
EDP-305 Dose 1 is being developed by Enanta Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ENTA. The company is conducting clinical trials to evaluate the drug's potential in treating Non-Alcoholic Steatohepatitis and RSV Infection.
EDP-305 Dose 1 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied for Non-Alcoholic Steatohepatitis and RSV Infection, with completed Phase 2 trials in both indications.
EDP-305 Dose 1 has been studied in two completed Phase 2 clinical trials. NCT03421431 assessed the drug in 134 subjects with Non-Alcoholic Steatohepatitis across multiple countries. NCT03691623 evaluated EDP-938, a related compound, in 179 healthy volunteers using an RSV challenge model in the United Kingdom.
EDP-305 Dose 1 and EDP-938 are distinct investigational compounds developed by Enanta Pharmaceuticals. EDP-305 Dose 1 is being studied for Non-Alcoholic Steatohepatitis, while EDP-938 was evaluated in an RSV challenge model. Both are small molecules in Phase 2 development, but they are not the same drug.